3-Morpholinosydnonimine (SIN-1) is a metabolite of molsidomine (sc-200337) which has been shown to decompose spontaneously in solution in the presence of oxygen. This reaction releases nitric oxide (NO) and superoxide anion, which under physiological conditions, react to produce peroxynitrite. SIN-1 is a potent vasodilator, activator of GCS (guanylyl cyclase), inhibitor of platelet aggregation, general cysteine protease inhibitor, and has been shown to produce significant protective effects in myocardial ischemia-reperfusion. Some of the effects of SIN-1 can be attenuated by nitroglycerin-induced tolerance.
1. Hogg, N., et al., 1992. Production of hydroxyl radicals from the simultaneous generation of superoxide and nitric oxide. The Biochemical journal. 281 ( Pt 2)(): 419-24. PMID: 1310595
2. Siegfried, M R., et al., 1992. Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion. The Journal of pharmacology and experimental therapeutics. 260(2): 668-75. PMID: 1738117
3. Henry, P J., et al., 1989. Nitroglycerin-induced tolerance affects multiple sites in the organic nitrate bioconversion cascade. The Journal of pharmacology and experimental therapeutics. 248(2): 762-8. PMID: 2563771
4. Nishikawa, M., et al., 1982. Inhibition of platelet aggregation and stimulation of guanylate cyclase by an antianginal agent molsidomine and its metabolites. The Journal of pharmacology and experimental therapeutics. 220(1): 183-90. PMID: 6118429
5. Lipton, S A., et al., 1993. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature. 364(6438): 626-32. PMID: 8394509
6. Ascenzi, P., et al., 2001. Inhibition of cysteine protease activity by NO-donors. Current protein & peptide science. 2(2): 137-53. PMID: 12370021
See how others have used 3-Morpholinosydnonimine. Click on the entry to view the PubMed entry .
PMID: # 27010352 Silina, YE. et al. 2016. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 1020: 6-13.
PMID: # 27158388 Xu, Z. et al. 2016. Am J Transl Res. 8: 1027-36.
PMID: # 24804999 Kinoshita, C. et al. 2014. Nat Commun. 5: 3823.
PMID: # 22210510 Aoyama, K. et al. 2012. Neurobiol. Dis. 45: 973-82.
PMID: # 21371533 Aoyama, K. et al. 2011. Neuroscience. 181: 206-15.
PMID: # 14742271 Kang, DH et al. 2004. Am. J. Pathology. 164: 679-688.
PMID: # 11352817 Banan, A. et al. 2001. Am. J. Physiol. Gastrointest. Liver Physiol. 280: G1234-G1246.
PMID: # 9388195 Narayan, S. et al. 1997. J. Biol. Chem. 272: 30619-30622.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.